AZD0095 is a selective and orally active Reduced tumor growth more efficiently than AZD0095 or AZD2171 alone.
[1]. Goldberg FW, et al. Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology. J Med Chem. 2022 Dec 16.
















